![]() Cantabio Pharmaceuticals Cantabio Pharmaceuticals Inc. is a biotechnology company focusing on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. | ![]() Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. | ![]() Hutchison China Meditech Hutchison China MediTech is a biopharmaceutical company, engaging in the research, development, manufacture and sale of pharmaceuticals and healthcare products. | ![]() Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. | ||
Founding Date | Founding Date 2009 | Founding Date 1996 | Founding Date 2000 | Founding Date 2000 | Founding Date 1849 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Palo Alto, US HQ Budapest, HU | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Shanghai, CN HQ Beijing, CN Jiangsu, CN Shanghai, CN Shanghai, CN Hong Kong, HK Hong Kong, HK see more | Locations Guang Zhou Shi, CN HQ | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more |
Employees | Employees 11 | Employees 75,883 | Employees 1,811 | Employees 1,814 | Employees 81,0008% decrease |
Valuation ($) | Valuation ($) 563.6 k | Valuation ($) N/A | Valuation ($) 3.6 b | Valuation ($) N/A | Valuation ($) 163.9 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $548.5m (FY, 2025) | Revenue (est.) ¥1.1b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $8.4b (FY, 2025) | Cost of goods $324.4m (FY, 2025) | Cost of goods ¥810m (FY, 2025) | Cost of goods $16.1b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $49.8b (FY, 2025) | Gross profit $224.2m (FY, 2025) | Gross profit ¥320.9m (FY, 2025) | Gross profit $46.5b (FY, 2025) |
Net income | Net income ($2m) (FY, 2018) | Net income $14b (FY, 2025) | Net income $435.1m (FY, 2025) | Net income ¥13.6m (FY, 2025) | Net income $7.8b (FY, 2025) |
Operating ⚠ | |||||
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 32 (FY, 2024) |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products 8 (FY, 2022) | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 5 (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised $ 100m | Total funding raised N/A | Total funding raised N/A |

Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View company
Hutchison China MediTech is a biopharmaceutical company, engaging in the research, development, manufacture and sale of pharmaceuticals and healthcare products.
View company
Quantum Hi-Tech (China) Biological is a biotechnology company.
View company
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View company